In the context of cancer, recent studies reported overexpression of TUBB2B in hepatocellular carcinoma (HCC), neuroblastoma, Hodgkin lymphoma and endocrine therapy-resistant breast cancer [9, 10]. Here, TUBB2B is linked to hepatocellular carcinoma.